Search - tctmd.com

Displaying 1 - 20 of 38

Sort: Relevancy | Date

Presentation NY Valves 2025

Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study

Presenter: Suzanne V. Arnold

June 26, 2025

Presentation NY Valves 2025

A Deep Dive Into the Quality-of-Life Evidence From TRILUMINATE and TRISCEND II

Presenter: Suzanne V. Arnold

June 26, 2025

Presentation NY Valves 2025

Effect of TTVR on Preference-Weighted Health Status: A Patient-Centered Sub-Study of the TRISCEND II Pivotal Trial

Presenter: Suzanne V. Arnold

June 25, 2025

Presentation TCT 2024

Who to Treat With TTVI?

Presenter: Suzanne Arnold

October 30, 2024

Presentation TCT 2024

How to Interpret Patient Reported Outcomes (PROs): Lessons from the Regulatory Approval Trials in TTVI

Presenter: Suzanne Arnold

October 30, 2024

Presentation NY Valves 2024

Assessing Functional Status and Predicting Clinical Improvement

Presenter: Suzanne V. Arnold

June 07, 2024

Presentation NY Valves 2024

The Importance of Patient Reported Outcomes in VHD

Presenter: Suzanne V. Arnold

June 06, 2024

Presentation NY Valves 2024

Interpretation of PROs: Understanding Validity and Clinically-Important Differences

Presenter: Suzanne V. Arnold

June 06, 2024

Presentation NY Valves 2024

The Importance of Patient Reported Outcomes in TR Clinical Studies

Presenter: Suzanne V. Arnold

June 06, 2024

Presentation TCT 2023

The Importance of Patient Reported Outcomes in TR Trials

Presenter: Suzanne Arnold

October 26, 2023

Presentation TCT 2023

Quality of Life After Transcatheter Tricuspid-Valve Repair vs. Medical Therapy in Patients with Severe Tricuspid Regurgitation: Results From the Randomized TRILUMINATE Pivotal Trial

Presenter: Suzanne Arnold

October 26, 2023

Presentation TCT 2023

Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation: The Tri-QOL Study

Presenter: Suzanne Arnold

October 25, 2023

Presentation TCT 2023

PROs are a Powerful Endpoint in TR Interventional Trials

Presenter: Suzanne Arnold

October 25, 2023

Presentation TCT 2022

Mediators of Improvement in TAVR Outcomes Over Time: Insights From the STS-ACC TVT Registry

Presenter: Suzanne Arnold

September 18, 2022

Presentation TCT 2021

Tricuspid Valve Interventions - Adding Quality of Life to Years, from Industry Perspective

Presenter: Suzanne Arnold

November 05, 2021

Presentation TCT 2021

Quality of Life Matters to Patients: How ISCHEMIA and ORBITA Have Informed Our Practice

Presenter: Suzanne Arnold

November 04, 2021

Presentation TCT 2020

TCT 354: Prognostic Importance of Functional Status Versus Health Status in Patients With Heart Failure and Severe Secondary Mitral Regurgitation

Presenter: Suzanne Arnold

October 14, 2020

Presentation TCT 2019

Perspectives on Real-World Economics in the Modern Era of TAVR

Presenter: Suzanne Arnold

September 27, 2019

Presentation ACC 2019

Health Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial

Presenter: Suzanne V. Arnold

March 18, 2019

Presentation TCT 2018

Case #8: A Case of Asymptomatic Leaflet Thrombosis: Management Strategies

Presenter: Philippe Genereux, Josep Rodés-Cabau, Suzanne V. Arnold, Wayne B. Batchelor, Pablo Lamelas, Tullio Palmerini, Shigeru Saito, Tobias Tichelbäcker

September 23, 2018

Advertisement

Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study

A Deep Dive Into the Quality-of-Life Evidence From TRILUMINATE and TRISCEND II

Effect of TTVR on Preference-Weighted Health Status: A Patient-Centered Sub-Study of the TRISCEND II Pivotal Trial

Who to Treat With TTVI?

How to Interpret Patient Reported Outcomes (PROs): Lessons from the Regulatory Approval Trials in TTVI

Assessing Functional Status and Predicting Clinical Improvement

The Importance of Patient Reported Outcomes in VHD

Interpretation of PROs: Understanding Validity and Clinically-Important Differences

The Importance of Patient Reported Outcomes in TR Clinical Studies

The Importance of Patient Reported Outcomes in TR Trials

Quality of Life After Transcatheter Tricuspid-Valve Repair vs. Medical Therapy in Patients with Severe Tricuspid Regurgitation: Results From the Randomized TRILUMINATE Pivotal Trial

Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation: The Tri-QOL Study

PROs are a Powerful Endpoint in TR Interventional Trials

Mediators of Improvement in TAVR Outcomes Over Time: Insights From the STS-ACC TVT Registry

Tricuspid Valve Interventions - Adding Quality of Life to Years, from Industry Perspective

Quality of Life Matters to Patients: How ISCHEMIA and ORBITA Have Informed Our Practice

TCT 354: Prognostic Importance of Functional Status Versus Health Status in Patients With Heart Failure and Severe Secondary Mitral Regurgitation

Perspectives on Real-World Economics in the Modern Era of TAVR

Health Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial

Case #8: A Case of Asymptomatic Leaflet Thrombosis: Management Strategies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content